The HPRA advises healthcare professionals not to retain printed versions of Summary of Product Characteristics (SPC) documents. As these documents are subject to frequent content updates, including changes to safety and dose related information, we recommend that you visit our website as necessary to access the most up-to-date versions. If you have any queries about specific SPCs on our website then please e-mail info@hpra.ie


Atripla

600/200/24 milligram(s) Film-coated tablet

Bristol-Myers Squibb Pharmaceuticals ucEU/1/07/430/001

Main Information

Trade NameAtripla
Active SubstancesEfavirenz
Emtricitabine
Tenofovir disoproxil fumarate
Strength600/200/24 milligram(s)
Dosage FormFilm-coated tablet
Licence HolderBristol-Myers Squibb Pharmaceuticals uc
Licence NumberEU/1/07/430/001

Group Information

ATC CodeJ05AR Antivirals for treatment of HIV infections, combinations
J05AR06 emtricitabine, tenofovir disoproxil and efavirenz

Status

Authorised/WithdrawnAuthorised
Licence Issued
Legal statusProduct subject to prescription which may not be renewed (A)
Supply StatusSupply through pharmacies only
Advertising StatusAdvertising to healthcare professionals only
Conditions of LicenceMedicinal product subject to restricted medical prescription (See Annex I: Summary of Product Characteristics, section 4.2)
Marketing StatusUnknown

Documents

Summary of Product CharacteristicsSearch EMA website
Package LeafletSearch EMA website
Public Assessment ReportSearch EMA website
« Back